Pfizer Quality Improvement Request for Proposals – Implementing Shared Decision Making in Hemophilia Patient Care is a competitive grant program designed to support quality improvement projects that integrate shared decision making tools, patient-reported outcomes applications, and care algorithms into hemophilia patient care across the United States.

Overview

Shared decision making is a vital component of the interaction between individuals living with hemophilia, their caregivers, and the multidisciplinary teams at hemophilia treatment centers. This competitive grant program aims to support Quality Improvement projects that embed SDM tools, patient-reported outcomes, and care algorithms into routine hemophilia care. Projects that utilize system-based changes will receive high priority.

Funding and Benefits

• Funding Range: Individual projects requesting up to $30,000 will be considered. The estimated total available budget for this RFP is $60,000.
• Project Length: Maximum project length is 18 months.
• Allowable Costs: Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
• Ineligible Costs: Pfizer does not provide funding for capital purchases such as equipment, software licenses, technology, or bricks and mortar. Equipment hire or leasing is acceptable. Grants cannot be used to purchase Pfizer therapeutic agents.

Eligibility

• Geographic Scope: Projects must be conducted in the United States.
• Applicant Organizations: Medical, dental, nursing, allied health, and pharmacy professional schools; healthcare institutions (both large and small); professional organizations; government agencies; and other entities with a mission related to healthcare improvement.
• Ineligible Entities: Only organizations are eligible to receive grants, not individuals or medical practice groups (e.g., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
• Collaborations: Collaborations within institutions, as well as between different institutions, organizations, or associations, are encouraged. All partners must have a relevant role, and the requesting organization must have a key role in the project.
• Project Lead: The applicant must be the Project Lead or Principal Investigator or an authorized designee. The Project Lead must be an employee or contractor of the requesting organization.
• Legal Requirement: The requesting organization must be legally able to receive award funding directly from Pfizer Inc.

Research Areas and Activities

The program supports projects focusing on the following areas:

• Implementing shared decision making tools and management of care algorithms into hemophilia patient care. Multi-disciplinary collaborations are encouraged when appropriate, but all partners must have a relevant role.
• Identifying significant barriers that contribute to geographic, gender, and racial healthcare disparities disproportionately impacting the hemophilia community, with the goal of enhancing early detection and determining targeted interventions that address these challenges with a focus on SDM.
• Exploring empowering strategies that enable patients to actively participate in their care and make informed decisions regarding disease management options, including systematically assessing and documenting patient views on treatment and its burden as a data point in SDM discussions.
• Implementing and evaluating patient-reported outcome tools in hemophilia care to capture the patient voice, improve understanding of treatment burden and quality of life, and support shared decision making. This includes exploring innovative strategies such as digital tools, remote monitoring, and structured assessment models.

Target Audience: People living with hemophilia, caregivers, and members of multidisciplinary teams that care for hemophilia patients, including hematologists, pharmacists, specialty nurses, orthopedists, genetic counsellors, and other physicians.

Note: This program does not support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Application Process

• Submission Portal: Applications must be submitted via the online portal at www.cybergrants.com/pfizer/QI. First-time users should click "Create your password."
• Application Steps: Click the "Start A New Quality Improvement Grant Application" button and complete all required sections of the online application. Upload the project proposal in the Proposal/Protocol field.
• Application Fields: For the question "Competitive Grant?" select "Yes." Select the Primary Area of Interest: Hemophilia. Select the Competitive Grant Program Name: 2026 RD US SDM Hemo QI.
• Proposal Requirements: Proposals should be single-spaced using Calibri 12-point font and 1-inch margins, with a 15-page limit exclusive of references. The proposal must address goals and objectives, assessment of need, target audience, project design and methods, innovation, evaluation and outcomes, anticipated timeline, additional information, organization detail, and budget detail.
• IRB Approval: Organizations must obtain approval from an Institutional Review Board if required for study execution. It is not mandatory to have IRB approval at the time of submission, but approval must be in place prior to 1 November 2026.
• Budget: A total amount requested is the only information needed at the Letter of Intent stage. Full budget is not required at that stage. Budget amounts must be in U.S. dollars.
• Review Process: Grant requests are reviewed by Pfizer to make final grant decisions. Applicants may be asked for additional clarification during the review period.
• Notification: All applicants will be notified via email by the dates noted below.

Deadline and Timeline

• RFP Release Date: 26 May 2026
• Submission Deadline: 21 July 2026 at 23:59 Eastern Standard Time (New York, GMT -5). Applications submitted after the due date will not be reviewed.
• Anticipated Grant Award Notification: 9 September 2026
• Anticipated Project Start Date: November 2026
• Anticipated Project End Date: May 2028

Contact Information

For questions regarding this RFP, direct them in writing to the Grant Officer, Talita Honorato-Rzeszewicz, at talita.honorato-rzeszewicz@pfizer.com with the subject line "2026 RD US SDM Hemo QI." For technical difficulties with the submission website, use the "Technical Questions" link at the bottom of the page in Cybergrants.